Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity. Hlaváč, M., Kováčiková, L., Prnová, M.Š., Šramel, P., Addová, G., Májeková, M., Hanquet, G., Boháč, A., Štefek, M. Journal of Medicinal Chemistry 2020, 63, 369-381. (https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01747)

Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands. Murár, M., Dobiaš, J., Šramel, P., Addová, G., Hanquet, G., Boháč, A. European Journal of Medicinal Chemistry 2017, 126, 754-761. (https://doi.org/10.1016/j.ejmech.2016.11.003)

Ynamide Click chemistry in development of triazole VEGFR2 TK modulators. Vojtičková, M., Dobiaš, J., Hanquet, G., Addová, G., Cetin-Atalay, R., Yildirim, D.C., Boháč, A. European Journal of Medicinal Chemistry 2015, 103, 105-122. (https://doi.org/10.1016/j.ejmech.2015.08.012)

A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex – Medicinal chemistry consequences of a TKs analysis. Lintnerová, L., García-Caballero, M., Gregáň, F., Melicherčík, M., Quesada, A.R., Dobiaš, J., Lác, J., Sališová, M., Boháč, A. European Journal of Medicinal Chemistry 2014, 72, 146-159. (https://doi.org/10.1016/j.ejmech.2013.11.023)

Preparation and Structural Analysis of Several New α,α,α′,α′-Tetraaryl-1,3-dioxolane-4,5-dimethanols (TADDOL's) and TADDOL analogs, their evaluation as titanium ligands in the enantioselective addition of methyltitanium and diethylzinc reagents to benzaldehyde, and refinement of the mechanistic hypothesis. Ito, Y.N., Ariza, X., Beck, A.K., Boháč, A., Ganter, C., Gawley, R.E., Kühnle, F.N.M., Tuleja, J., Wang, Y.M., Seebach, D. Helvetica Chimica Acta 1994 77, 2071-2110. (https://doi.org/10.1002/hlca.19940770802)

Inhibition of Glycolysis Suppresses Cell Proliferation and Tumor Progression In Vivo: Perspectives for Chronotherapy. Horváthová, J., Moravčík, R., Matúšková, M., Šišovský, V., Boháč, A., Zeman, M. International Journal of Molecular Sciences 2021, 22, 4390. (https://doi.org/10.3390/ijms22094390)

Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity. Hlaváč, M., Kováčiková, L., Prnová, M.Š., Šramel, P., Addová, G., Májeková, M., Hanquet, G., Boháč, A., Štefek, M. Journal of Medicinal Chemistry 2020, 63, 369-381. (https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01747)

Switchable highly regioselective synthesis of 3,4-dihydroquinoxalin-2(1H)ones from o-phenylenediamines and aroylpyruvates. Dobiaš, J., Ondruš, M., Addova, G., Bohač, A. Beilstein Journal of Organic Chemistry 2017, 13, 1350-1360. (https://doi.org/10.3762/bjoc.13.132)

Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands. Murár, M., Dobiaš, J., Šramel, P., Addová, G., Hanquet, G., Boháč, A. European Journal of Medicinal Chemistry 2017, 126, 754-761. (https://doi.org/10.1016/j.ejmech.2016.11.003)

Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Kimani, S.G., Kumar, S., Davra, V., Chang, Y.-J., Kasikara, C., Geng, K., Tsou, W.-I., Wang, S., Hoque, M., Boháč, A., Lewis-Antes, A., De Lorenzo, M.S., Kotenko, S.V., Birge, R.B. Cell Communication and Signaling 2016, 14, 19. (https://dx.doi.org/10.1186%2Fs12964-016-0142-1)

Journal of Medicinal Chemistry 2020, 63, 369: Novel 3,4-dihydroquinolin-2(1H)-one derivatives as dual inhibitor targeting AKR1B1/ROS for treatment of diabetic complications: Design, synthesis and biological evaluation. Han, Z., Qi, G., Zhu, J., Zhang, Y., Xu, Y., Yan, K., Zhu, C., Hao, X.(2020) Bioorganic Chemistry, 105, art. no. 104428.

Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus. Kousaxidis, A., Petrou, A., Lavrentaki, V., Fesatidou, M., Nicolaou, I., Geronikaki, A.(2020) European Journal of Medicinal Chemistry, 207, art. no. 112742.

[4 + 2]-Annulation of Prop-2-ynylsulfonium Salts and Isatoic Anhydrides: Access to 3-Methylthio-4-quinolones. Chen, Q., Pan, Y., Yue, T., Yang, W., Liu, H., Zheng, J. (2020) Organic Letters, 22 (15), pp. 6096-6100.

Oxidative degradation of high-molar-mass hyaluronan: Effects of some indole derivatives to hyaluronan decay. Valachová, K., Mach, M., Šoltés, L. (2020) International Journal of Molecular Sciences, 21 (16), art. no. 5609, pp. 1-12.

European Journal of Medicinal Chemistry 2017, 126, 754: Current scenario of 1,3-oxazole derivatives for anticancer activity. Yan, X., Wen, J., Zhou, L., Fan, L., Wang, X., Xu, Z. (2020) Current Topics in Medicinal Chemistry, 20 (21), pp. 1916-1937. Cited 1 time.

Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors. El Kerdawy, A.M., Osman, A.A., Zaater, M.A. (2019) Journal of Molecular Modeling, 25 (6), art. no. 171, . Cited 9 times.

Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention Uzor, S., Zorzou, P., Bowler, E., Porazinski, S., Wilson, I., Ladomery, M.

(2018) Gene, 670, pp. 46-54. Cited 11 times.

Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells. Bowler, E., Porazinski, S., Uzor, S., Thibault, P., Durand, M., Lapointe, E., Rouschop, K.M.A., Hancock, J., Wilson, I., Ladomery, M. (2018) BMC Cancer, 18 (1), art. no. 355, . Cited 32 times.

Preparation of oxazolines and oxazoles via a PhI(OAc)2-promoted cyclization of N-propargylamides Yi, W., Liu, Q.-Y., Fang, X.-X., Lou, S.-C., Liu, G.-Q.

(2018) Organic and Biomolecular Chemistry, 16 (38), pp. 7012-7018. Cited 16 times.

European Journal of Medicinal Chemistry 2015, 103, 105: Recent advance in oxazole-based medicinal chemistry. Zhang, H.-Z., Zhao, Z.-L., Zhou, C.-H.(2018) European Journal of Medicinal Chemistry, 144, pp. 444-492. Cited 115 times.

An investigation on the second-order nonlinear optical response of cationic bipyridine or phenanthroline iridium(iii) complexes bearing cyclometallated 2-phenylpyridines with a triphenylamine substituent. Hierlinger, C., Cordes, D.B., Slawin, A.M.Z., Colombo, A., Dragonetti, C., Righetto, S., Roberto, D., Jacquemin, D., Zysman-Colman, E., Guerchais, V. (2018) Dalton Transactions, 47 (25), pp. 8292-8300. Cited 13 times.

Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer. Bistrović, A., Krstulović, L., Harej, A., Grbčić, P., Sedić, M., Koštrun, S., Pavelić, S.K., Bajić, M., Raić-Malić, S.(2018) European Journal of Medicinal Chemistry, 143, pp. 1616-1634. Cited 32 times.

Mechanistic applications of click chemistry for pharmaceutical drug discovery and drug delivery. Meghani, N.M., Amin, H.H., Lee, B.-J.

(2017) Drug Discovery Today, 22 (11), pp. 1604-1619. Cited 43 times.

The 1,2,3-triazole ring as a bioisostere in medicinal chemistry. Bonandi, E., Christodoulou, M.S., Fumagalli, G., Perdicchia, D., Rastelli, G., Passarella, D. (2017) Drug Discovery Today, 22 (10), pp. 1572-1581. Cited 220 times.

European Journal of Medicinal Chemistry 2014, 72, 146: Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. Eissa, I.H., El-Helby, A.-G.A., Mahdy, H.A., Khalifa, M.M., Elnagar, H.A., Mehany, A.B.M., Metwaly, A.M., Elhendawy, M.A., Radwan, M.M., ElSohly, M.A., El-Adl, K.

(2020) Bioorganic Chemistry, 105, art. no. 104380, . Cited 9 times.

Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Mahdy, H.A., Ibrahim, M.K., Metwaly, A.M., Belal, A., Mehany, A.B.M., El-Gamal, K.M.A., El-Sharkawy, A., Elhendawy, M.A., Radwan, M.M., Elsohly, M.A., Eissa, I.H.

(2020) Bioorganic Chemistry, 94, art. no. 103422, . Cited 35 times.

Recent advance in oxazole-based medicinal chemistry. Zhang, H.-Z., Zhao, Z.-L., Zhou, C.-H. (2018) European Journal of Medicinal Chemistry, 144, pp. 444-492. Cited 115 times.

Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz, M.A., Abdel-Mohsen, H.T., El Kerdawy, A.M., Ragab, F.A.F., Ali, M.M., Abu-bakr, S.M., Girgis, A.S., El Diwani, H.I. (2017) European Journal of Medicinal Chemistry, 136, pp. 315-329. Cited 35 times.

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Zhang, J., Jiang, X., Jiang, Y., Guo, M., Zhang, S., Li, J., He, J., Liu, J., Wang, J., Ouyang, L.

(2016) European Journal of Medicinal Chemistry, 108, pp. 495-504. Cited 54 times.

Helvetica Chimica Acta 1994 77, 2071: Quantitative Structure-Selectivity Relationships in Enantioselective Catalysis: Past, Present, and Future. Zahrt, A.F., Athavale, S.V., Denmark, S.E. (2020) Chemical Reviews, 120 (3), pp. 1620-1689. Cited 34 times.

Enhancement of the Catalytic Activity of Chiral H8-BINOL Titanium Complexes by Introduction of Sterically Demanding Groups at the 3-Position. Hayashi, Y., Yamamura, N., Kusukawa, T., Harada, T. (2016) Chemistry - A European Journal, 22 (34), pp. 12095-12105. Cited 10 times.

Catalytic Synthesis of Enantiopure Chiral Alcohols via Addition of Grignard Reagents to Carbonyl Compounds. Collados, J.F., Solaì, R., Harutyunyan, S.R., Maciá, B. (2016) ACS Catalysis, 6 (3), pp. 1952-1970. Cited 38 times.

Enantioselective titanium-promoted 1,2-additions of carbon nucleophiles to carbonyl compounds. Pellissier, H. (2015) Tetrahedron, 71 (17), pp. 2487-2524. Cited 34 times.

Trans-hydrogenation: Application to a concise and scalable synthesis of brefeldin. Fuchs, M., Fürstner, A. (2015) Angewandte Chemie - International Edition, 54 (13), pp. 3978-3982. Cited 67 times.

Medicinal chemistry – an efficient development of inhibitors of selected key biological targets connected with tumor progression; 2018-2021; VEGA 1/0670/18

Multi-target paradigm for innovative ligand identification in the drug discovery process; 2016-2020; COST CA15135

Development of organic SMO tyrosine kinase modulators as drug candidates; 2016-2017; APVV-SK-FR-2015-0014

Syntéza a biologické testovanie počítačom navrhnutých inhibítorov VEGFR-2 kinázy, aplikácia poznatkov pre vývoj inhibítorov ovplyvňujúcich rezistenciu rakovinových kmeňových buniek; 2013-2016; VEGA 1/0634/13

Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells; 2012-2016; COST CM1106